Real-world evidence is a critical issue for the FDA, but we must work together to ensure it meets the highest possible standards, says former FDA Commissioner, Robert Califf
Companies must demonstrate meaningful clinical outcomes to guarantee access to their medicines, says Patricia Andrews, the new CEO of Boston Biomedical
ICER has the laudable mission of being an independent, trusted source of value assessment for medicines. We spoke to Chief Scientific Officer, Dan Ollendorf, about controversy, criticism and the power of collaboration.